Novartis Beheer

Beheer criteriumcontroles 2/4

De CEO Novartis is Vas Narasimhan, benoemd in Feb2018, heeft een ambtstermijn van 6.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 15.78M, bestaande uit 13.7% salaris en 86.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.016% van de aandelen van het bedrijf, ter waarde CHF 29.82M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.2 jaar en 8.8 jaar.

Belangrijke informatie

Vas Narasimhan

Algemeen directeur

US$15.8m

Totale compensatie

Percentage CEO-salaris	13.7%
Dienstverband CEO	6.8yrs
Eigendom CEO	0.02%
Management gemiddelde ambtstermijn	3.2yrs
Gemiddelde ambtstermijn bestuur	8.8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Vas Narasimhan's beloning veranderd ten opzichte van Novartis's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	US$12b
Jun 30 2024	n/a	n/a	US$10b
Mar 31 2024	n/a	n/a	US$9b
Dec 31 2023	US$16m	US$2m	US$9b
Sep 30 2023	n/a	n/a	US$7b
Jun 30 2023	n/a	n/a	US$7b
Mar 31 2023	n/a	n/a	US$6b
Dec 31 2022	US$12m	US$2m	US$6b
Sep 30 2022	n/a	n/a	US$21b
Jun 30 2022	n/a	n/a	US$22b
Mar 31 2022	n/a	n/a	US$24b
Dec 31 2021	US$12m	US$2m	US$23b
Sep 30 2021	n/a	n/a	US$10b
Jun 30 2021	n/a	n/a	US$9b
Mar 31 2021	n/a	n/a	US$8b
Dec 31 2020	US$12m	US$2m	US$8b
Sep 30 2020	n/a	n/a	US$7b
Jun 30 2020	n/a	n/a	US$7b
Mar 31 2020	n/a	n/a	US$7b
Dec 31 2019	US$12m	US$2m	US$7b
Sep 30 2019	n/a	n/a	US$7b
Jun 30 2019	n/a	n/a	US$7b
Mar 31 2019	n/a	n/a	US$13b
Dec 31 2018	US$10m	US$2m	US$13b
Sep 30 2018	n/a	n/a	US$14b
Jun 30 2018	n/a	n/a	US$14b
Mar 31 2018	n/a	n/a	US$8b
Dec 31 2017	US$5m	US$864k	US$7b

Compensatie versus markt: De totale vergoeding ($USD 15.78M ) Vas } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de UK markt ($USD 5.73M ).

Compensatie versus inkomsten: De vergoeding van Vas is het afgelopen jaar met meer dan 20% gestegen.

CEO

Vas Narasimhan (48 yo)

6.8yrs

Tenure

US$15,778,038

Compensatie

Dr. Vasant Narasimhan, also known as Vas, M.D., serves as Chief Executive Officer of Novartis AG at Novartis India Ltd. Dr. Narasimhan has been Chief Executive Officer of Novartis AG since February 1, 2018...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Vasant Narasimhan	Chief Executive Officer	6.8yrs	US$15.78m	0.016% CHF 29.8m
Harry Kirsch	Chief Financial Officer	11.5yrs	US$7.76m	0.019% CHF 34.5m
Victor Bulto	President of US	2.6yrs	US$6.13m	0.0017% CHF 3.1m
Patrick Horber	President of International	less than a year	US$7.95m	0.0014% CHF 2.5m
Steffen Lang	President of Operations	2.6yrs	US$4.17m	0.0077% CHF 13.9m
Paul Penepent	Head of Group Financial Reporting and Accounting	no data	geen gegevens	geen gegevens
Sloan Simpson	Global Head of Investor Relations	less than a year	geen gegevens	geen gegevens
Klaus Moosmayer	Chief Ethics	5.9yrs	US$2.67m	0.0019% CHF 3.4m
Karen Hale	Chief Legal Officer	3.5yrs	US$4.16m	0.0012% CHF 2.2m
Robert Kowalski	Chief People & Organization Officer	3.2yrs	US$3.45m	0.0011% CHF 1.9m
Etienne Jousseaume	Head of Market Access	no data	geen gegevens	geen gegevens
Linda Armstrong	Global Head of Respiratory Development	no data	geen gegevens	geen gegevens

3.2yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van NOVNz wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Sidonie Golombowski-Daffner	Chairperson & President of Advanced Accelerator Applications	no data	geen gegevens	geen gegevens
Simon Moroney	Independent Vice Chairman of the Board	4.8yrs	US$546.92k	0.00030% CHF 546.2k
Daniel Vasella	Honorary Chairman	no data	US$3.34m	geen gegevens
Bridgette Heller	Independent Non-Executive Director	4.8yrs	US$511.25k	0.00031% CHF 564.4k
Joerg Reinhardt	Independent Non-Executive Chairman	11.3yrs	US$4.52m	0.033% CHF 59.7m
François van Houten	Independent Non-Executive Director	7.8yrs	US$469.25k	0.00086% CHF 1.6m
Ton Buechner	Independent Non-Executive Director	8.8yrs	US$504.92k	0.0011% CHF 2.1m
William Winters	Independent Non-Executive Director	11.8yrs	US$428.02k	0.0015% CHF 2.8m
Charles Sawyers	Independent Non-Executive Director	11.8yrs	US$428.02k	0.00087% CHF 1.6m
Patrice Bula	Lead Independent Director	5.8yrs	US$491.97k	0.00056% CHF 1.0m
Nancy Andrews	Independent Non-Executive Director	9.8yrs	US$428.02k	0.00053% CHF 964.9k
Elizabeth Doherty	Independent Non-Executive Director	8.8yrs	US$535.03k	0.00074% CHF 1.3m

8.8yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van NOVNz wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.8 jaar).

Novartis Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Novartis AG, Annual General Meeting, Mar 07, 2025

Recent updates

Novartis' Scemblix® Receives Approval from US Food and Drug Administration

Novartis Raises Earnings Guidance for the Fiscal Year 2024

Novartis AG, Annual General Meeting, Mar 07, 2025

Alkem Labs Reportedly in Talks to Acquire Novartis India from Its Swiss Parent

Novartis Announces Positive Topline Results from Twice-Yearly Leqvio (Inclisiran) in the Phase III V-Mono Study

Siemens Healthineers Offers to Buy Novartis Molecular Imaging Business

Novartis Receives FDA Accelerated Approval for Fabhalta (iptacopan)

Novartis AG to Report Q4, 2024 Results on Jan 31, 2025

Novartis AG to Report Q4, 2024 Results on Jan 31, 2025

Novartis AG Presents Latest Phase III Fabhalta®? (iptacopan) Data in C3 Glomerulopathy (C3G)

Novartis AG (SWX:NOVN) entered into an agreement to acquire Mariana Oncology, Inc. from Atlas Venture L.P., Access Biotechnology, RA Capital Management, L.P., Deep Track Capital, LP, Forbion Capital Partners B.V. and others for $1.8 billion.

Novartis and Medicines for Malaria Venture Announce Positive Efficacy and Safety Data for A Novel Treatment for Babies

Novartis AG Revise Earnings Guidance for the Year 2024

Novartis' Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthritis Treatment, While Pending Launch of UCB’s Bimzelx Poised to Further Disrupt the Market

Novartis Presents Results from Pre-Specified Interim Analysis of the Phase III APPLAUSE-IgAN study of Fabhalta

Novartis Fabhalta Receives Positive CHMP Opinion as First Oral Monotherapy for Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Novartis AG (SWX:NOVN) acquired IFM Due, Inc. from IFM Therapeutics, LLC for approximately $840 million.

Dr. Reddy's Laboratories Denies in Race to Acquire Novartis' Stake in Novartis India

Dr Reddy's Reportedly May Join Race to Acquire Novartis' India Arm

Novartis AG Announces FDA Approves Xolair® (Omalizumab) as First and Only Medicine for Children and Adults with One or More Food Allergies

Novartis Reportedly in Lead to Acquire MorphoSys

Novartis AG Provides Earnings Guidance for the Year 2024

Novartis AG to Report Q1, 2024 Results on Apr 23, 2024

Novartis AG Presents Data from the Phase III NETTER-2 Trial

Novartis AG Presents Data from the Phase III NETTER-2 Trial

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd